Phase 1 Large Cell Neuroendocrine Carcinoma Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 1Phase 2
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Molecular Partners AG138 enrolled3 locationsNCT07278479
Recruiting
Phase 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled5 locationsNCT07006727
Recruiting
Phase 1
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.162 enrolled3 locationsNCT06424665
Recruiting
Phase 1
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Phase 1
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer Extensive StageLarge Cell Neuroendocrine Carcinoma of the Lung
Legend Biotech USA Inc41 enrolled4 locationsNCT05680922
Recruiting
Phase 1
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma
Shanghai Simnova Biotechnology Co.,Ltd.35 enrolled1 locationNCT06384482